Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: taurine Clear all
Completed Phase 4 Interventional Results available

Acamprosate in Alcoholics With Comorbid Anxiety or Depression

NCT00330174
View directory record Official record
Conditions
Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
Interventions
Acamprosate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Belmont, Massachusetts • New York, New York • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 21, 2026, 9:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Taurine Therapy for SSADH Deficiency

NCT01608178
View directory record Official record
Conditions
Succinic Semialdehyde Dehydrogenase
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Acamprosate in Youth With Fragile X Syndrome

NCT01300923
View directory record Official record
Conditions
Fragile X Syndrome, Autism Spectrum Disorders
Interventions
Acamprosate
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

Biomarker Study of Acamprosate in Schizophrenia

NCT00688324
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Acamprosate
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Acamprosate Treatment: Mechanisms of Action

NCT00004552
View directory record Official record
Conditions
Alcoholism
Interventions
acamprosate (Campral)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Investigation of Dietary Supplement Liquid Shot Products on Mental Energy, Cognition (Acuity),and Mood

NCT06384586
View directory record Official record
Conditions
Cognition, Mental Fatigue, Mood
Interventions
Placebo shot, Functional energy shot
Dietary Supplement
Lead sponsor
The Water Street Collective
Industry
Eligibility
18 Years to 30 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iselin, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Energy Drinks

NCT02727920
View directory record Official record
Conditions
Energy Drinks
Interventions
Energy drink, Placebo
Dietary Supplement · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 70 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 21, 2026, 9:57 AM EDT
Recruiting Phase 4 Interventional

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

NCT06269627
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate calcium, Placebo
Drug · Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

NCT03818191
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Center City, Minnesota • Rochester, Minnesota • Newberg, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 21, 2026, 9:57 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

NCT02064010
View directory record Official record
Conditions
Drug-induced Tardive Dyskinesia
Interventions
SNC-102, Placebo
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

NCT00463346
View directory record Official record
Conditions
Alcohol Dependence, Schizophrenia
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 4 Interventional Results available

Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic

NCT00381043
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 21, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional

Daily Amino Acid Supplementation for People With Parkinson's Disease

NCT07115563
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Targeted Amino Acid Supplement, Control (placebo)
Dietary Supplement
Lead sponsor
Cristina Colon-Semenza
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Farmington, Connecticut • Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 9:57 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

NCT00640952
View directory record Official record
Conditions
Parkinson's Disease
Interventions
acamprosate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

NCT00571922
View directory record Official record
Conditions
Methamphetamine Dependence, Treatment Seeking
Interventions
Acamprosate, placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 21, 2026, 9:57 AM EDT
Withdrawn Early Phase 1 Interventional

Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth

NCT03420976
View directory record Official record
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
Novel Supplement Based Therapy
Dietary Supplement
Lead sponsor
Atrium Innovations
Industry
Eligibility
19 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Oxford, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated Not applicable Interventional

Effects of TUDCA on Endothelial Function in Type 2 DM

NCT03462940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Response, Endothelial Dysfunction
Interventions
Tauroursodeoxycholic acid
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated Phase 1 Interventional

Taurine in Adolescents With Bipolar Disorder

NCT00391001
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Taurine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
13 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Belmont, Massachusetts • Medford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 21, 2026, 9:57 AM EDT
Withdrawn Phase 2 Interventional

A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome

NCT02217007
View directory record Official record
Conditions
Tourette Syndrome
Interventions
SNC-102 sustained release tablet
Drug
Lead sponsor
Synchroneuron Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 21, 2026, 9:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Energy Drink Ingredients on Cardiovascular Function in Men and Women 18-39 Years Old

NCT04149717
View directory record Official record
Conditions
Cardiac Arrhythmia, Blood Pressure
Interventions
Energy Drink Ingredients and Exercise
Dietary Supplement
Lead sponsor
Duquesne University
Other
Eligibility
18 Years to 39 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Assess the Effects of a Vitamin Shot on Energy Levels

NCT06019858
View directory record Official record
Conditions
Energy, Fatigue, Mood, Weight Loss, Cognition
Interventions
Vitamin Energy Shot
Other
Lead sponsor
Vitamin Energy®
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 3 Interventional

COMBINE (Acamprosate/Naltrexone)

NCT00006206
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
12
States / cities
New Haven, Connecticut • Miami, Florida • Belmont, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated Phase 4 Interventional Results available

Study of Acamprosate to Prevent Alcohol Relapse in Criminal Justice Supervisees

NCT00249379
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 21, 2026, 9:57 AM EDT